Triple-negative breast cancer is the tumor that lacks expressions of estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor-2(HER2). A regular chemotherapy cannot eradicate triple-negative breast cancer. In the present study, we aimed to develop a combined use of daunorubicin and rofecoxib to treat triple-negative breast cancer, and reveal the underlying mechanisms. A gradient elution HPLC-UV method was developed for quantification, and the evaluations were performed on ...
【基金】
National Natural Science Foundation of China(Grant No.81373343);
the Key Grant of Beijing Natural Science Foundation(Grant No.7131009)
【更新日期】
2016-06-16
【分类号】
R737.9
【正文快照】
1.Introduction Breast cancer is the most frequently diagnosed cancerand the leading cause of cancer death among females[1].Approximately 12%to 17%breast cancer is the triple-negative breast cancer[2],which is defined as the tumorthat lacks expressions of
| 
推荐 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
